In contrast, patients in the PEONY study who received the neoadjuvant chemotherapy PTH*4 regimen achieved a tpCR rate of 39.3% postoperatively as determined by an independent review committee, while those with ER/PR-negative, HER2-positive breast cancer achieved a tpCR rate of 52.5% (17). Here, ERBB2 is linked to breast carcinoma.